OZEMRoundhill Glp-1 & Weight Loss ETF
Seeks capital appreciation.
By Roundhill Investments · Launched 2024
Annual Cost
0.59%
#3,222 of 6,040 · average
Fund Size
$64M
#3,502 of 6,040 · mid-size
Return (1Y)
+21.2%
Track Record
2 years
#3,502 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$12,072+20.7%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundHoldings
By weightConcentration
Top 10 holdings = 75.6% of fundconcentrated
Eli Lilly & Co
16.1%
Novo Nordisk A/S
13.1%
Mount Vernon Liquid Assets Portfolio, LLC
12.1%
Pfizer Inc
7.6%
Viking Therapeutics Inc
5.3%
Innovent Biologics Inc
5.1%
Ascletis Pharma Inc
4.7%
Amgen Inc
3.9%
Roche Holding AG
3.9%
AstraZeneca PLC
3.8%
Asset allocation
Stocks
99.1%
Cash
0.6%
Other
0.3%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
23.6%High
Year-on-year price swings
Max drawdown
-28.6%Moderate
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks capital appreciation.
- Strategy
- Actively manages a portfolio focused on equity securities of GLP-1 & Weight Loss Companies, prioritizing those involved in developing drugs for weight loss. Concentrates investments in the health care sector, including small-, mid-, and large-cap companies in both U.S. and non-U.S. markets.
- Inception date
- May 20, 2024
- Fund family
- Roundhill Investments
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save OZEM to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18